Log in to search using one of your social media accounts:


Here Come More Gene Therapies -- And More Pricing Debates

Gene therapies like Spark Therapeutics'upcoming Luxturna and Novartis'FDA-approved Kymriah are raising concerns about the rising cost of health care, leading some experts to suggest new ways to price treatments based on the benefits they offer.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: NASDAQ:ONCE Source Type: news

Related Links:

More News: Gene Therapy | Genetics | Health Management | Pharmaceuticals